SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Diabetes Metab J. 2025;49(4):565-579.

Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives.

, ,

제1저자 임수, 남가은 · 교신저자 Arya M Sharma

PMID 40499580 PMC12270583 DOI 10.4093/dmj.2025.0278 IF 8.2 내분비대사내과
소속 (3)
  1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  2. Department of Family Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
  3. Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are among the most urgent global public health challenges, yet differ markedly in recognition and management across medical, social, infrastructure, and policy domains. T2DM is supported by clear diagnostic criteria, defined treatment targets, and broad acceptance as a chronic disease. In contrast, obesity is assessed using imprecise metrics like body mass index, lacks standardized treatment goals, and is often misunderstood as a lifestyle issue rather than a chronic, relapsing disease. This misconception contributes to stigma, discrimination, and unrealistic patient expectations. T2DM receives substantial research funding, comprehensive clinical guidelines, and structured medical education, with strong support from large professional societies and multidisciplinary care models. Obesity care remains underfunded, inconsistently delivered, and underrepresented in medical training. Public health and policy efforts strongly favor T2DM, providing coordinated programs, insurance coverage, and regulatory oversight. Conversely, obesity is marginalized, with limited policy influence and a largely unregulated commercial weight-loss industry. Bridging these disparities requires adopting lessons from T2DM management-such as evidence-based guidelines, improved provider training, expanded insurance coverage, and public health strategies-to enhance obesity care and recognize it as a chronic disease requiring long-term, structured management.

Keywords

Chronic diseaseDiabetes mellitus, type 2Education, medicalHealth policyHealthcare disparitiesInsurance coverageObesity

Figures

Fig. 1.
Fig. 1. Type 2 diabetes mellitus vs. obesity: key differences in the medical aspect.
Fig. 2.
Fig. 2. Type 2 diabetes mellitus vs. obesity: key differences in the social and public health aspect.
Fig. 3.
Fig. 3. Lessons from type 2 diabetes mellitus for obesity treatment.

그림 출처: PubMed Central 공개 논문 (PMC12270583)

Conflict of interest statement

CONFLICTS OF INTEREST . Soo Lim received research grants from Merck Sharp & Dohme, Novo Nordisk, and LG Chem; and honoraria as a consultant or speaker for AstraZeneca, Boehringer Ingelheim, Abbott, LG Chem, Daewoong Pharmaceutical, Chong Kun Dang Pharmaceutical, and Novo Nordisk. Arya M. Sharma received honoraria from Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Currax, Oviva, and Vivus. Ga Eun Nam reported no potential conflict of interest relevant to this article.

그 밖의 정보
출판 형태
Journal Article, Review
저널
Diabetes & metabolism journal · eISSN 2233-6087
전자 출판
2025-06-11
MeSH
Humans · Diabetes Mellitus, Type 2* / therapy / epidemiology · Obesity* / therapy / epidemiology / complications · Public Health* · Obesity Management*
참고문헌
88편